Firma Immunic, Autor bei News-Research

Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board

17. November 202013. Dezember 2023 Firma ImmunicPosted in FirmeninternTagged anatomic, clinical, colitis, fiscal, immunic, immunic's, imu, lupus, market, patients, revenue, securities, statements, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the formation of a Scientific-Medical […]

Immunic, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update

6. November 202013. Dezember 2023 Firma ImmunicPosted in Finanzen / BilanzenTagged calvid, dosing, immunic, immunic's, imu, market, patients, revenue, rrms, statements, syndrome, uhcw, unblinded, vtl, with

– Released Very Positive Phase 2 Data for IMU-838 in Relapsing-Remitting Multiple Sclerosis; Company to Submit End-of-Phase 2 Meeting Requests to Regulatory Authorities at the End of Q1 2021 […]

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed

2. November 202013. Dezember 2023 Firma ImmunicPosted in Forschung und EntwicklungTagged calvid, cell, cells, fiscal, immunic, immunic's, imu, market, patients, revenue, securities, statements, syndrome, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that the company has enrolled and […]

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy

20. Oktober 202013. Dezember 2023 Firma ImmunicPosted in Forschung und EntwicklungTagged calvid, fiscal, hepatitis, immunic, immunic's, imu, innovfin, market, patients, revenue, statements, syndrome, ulcerative, vaccines, with

European Investment Bank and Immunic sign a financing agreement of up to €24.5 million to support the development of Immunic’s lead asset, IMU-838, in moderate COVID-19 IMU-838 is an orally […]

Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19

28. September 202013. Dezember 2023 Firma ImmunicPosted in Forschung und EntwicklungTagged calvid, dynamics, fiscal, immunic, immunic's, imu, market, patients, revenue, securities, statements, syndrome, ulcerative, unblinded, with

Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020

11. September 202013. Dezember 2023 Firma ImmunicPosted in Forschung und EntwicklungTagged 45mg, brain, dosing, immunic, immunic's, imu, market, neutropenia, patients, revenue, rrms, statements, syndrome, vidofludimus, with

Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppression Across Different Populations T ime Course of MRI Lesion Suppression Shows Reduction of Lesions Already Present at First Post-Baseline Scan […]